Clearside Biomedical, Inc. — Investor Relations & Filings

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye. The company is a leader in suprachoroidal space (SCS) drug administration, having developed the proprietary SCS Microinjector®, which is the first and only FDA-approved technology for accessing this area. This platform enables targeted delivery of therapeutics directly to the site of retinal diseases. Its first commercial product is XIPERE® (triamcinolone acetonide injectable suspension), approved for the treatment of macular edema associated with uveitis. Clearside's clinical pipeline is focused on serious retinal conditions, with its lead candidate, CLS-AX (a tyrosine kinase inhibitor), in late-stage development for wet age-related macular degeneration (wet AMD).